Answers to 5 Common Questions About Acute Exacerbations of COPD

被引:1
作者
Anzueto, Antonio R. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA
关键词
chronic obstructive pulmonary disease; disease exacerbation; disease progression; corticosteroids; antibiotics; OBSTRUCTIVE PULMONARY-DISEASE; RISK-FACTORS; TIME-COURSE; SALMETEROL; TIOTROPIUM; HEALTH; MANAGEMENT; RECOVERY;
D O I
10.3810/pgm.2009.09.2063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are major causes of morbidity and mortality in COPD, they must be prevented when possible and when they occur, treated aggressively. This article answers 5 of the most common questions I receive about AECOPDs: 1) Are worsening respiratory symptoms an acute exacerbation or disease progression? 2) What is the best first-line treatment for an AECOPD? 3) Would systemic steroids be an effective treatment? 4) When should antibiotics be considered? 5) Is it possible to prevent an AECOPD? The physician should not assume that exacerbations are part of the disease process; they can be treated and their frequency can be reduced with appropriate preventive measures. Treatment needs to be tailored to disease severity and patient risk factors, including bacterial resistance, which significantly affects patient outcomes. Studies are also showing that exacerbations can be prevented by maintenance therapy with either long-acting beta-agonists or tiotropium.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 24 条
  • [1] Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease - A randomized trial
    Aaron, Shawn D.
    Vandemheen, Katherine L.
    Fergusson, Dean
    Maltais, Francois
    Bourbeau, Jean
    Goldstein, Roger
    Balter, Meyer
    O'Donnell, Denis
    McIvor, Andrew
    Sharma, Sat
    Bishop, Graham
    Anthony, John
    Cowie, Robert
    Field, Stephen
    Hirsch, Andrew
    Hernandez, Paul
    Rivington, Robert
    Road, Jeremy
    Hoffstein, Victor
    Hodder, Richard
    Marciniuk, Darcy
    McCormack, David
    Fox, George
    Cox, Gerard
    Prins, Henry B.
    Ford, Gordon
    Bleskie, Dominique
    Doucette, Steve
    Mayers, Irvin
    Chapman, Kenneth
    Zamel, Noe
    FitzGerald, Mark
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) : 545 - U15
  • [2] [Anonymous], 1997, MMWR Recomm Rep, V46, P1
  • [3] [Anonymous], 2008, GLOB STRAT DIAGN MAN
  • [4] [Anonymous], COCHRANE DATABASE SY
  • [5] Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence
    Bach, PB
    Brown, C
    Gelfand, SE
    McCrory, DC
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 600 - 620
  • [6] Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
    Brusasco, V
    Hodder, R
    Miravitlles, M
    Korducki, L
    Towse, L
    Kesten, S
    [J]. THORAX, 2003, 58 (05) : 399 - 404
  • [7] BURGE S, 2003, EUR RESPIR J, V41, P46, DOI DOI 10.1183/09031936.03.00078002
  • [8] Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Calverley, Peter M. A.
    Anderson, Julie A.
    Celli, Bartolome
    Ferguson, Gary T.
    Jenkins, Christine
    Jones, Paul W.
    Yates, Julie C.
    Vestbo, Jorgen
    Calverley, P. M. A.
    Anderson, J. A.
    Celli, B.
    Ferguson, G. T.
    Jenkins, C.
    Jones, P. W.
    Knobil, K.
    Yates, J. C.
    Vestbo, J.
    Cherniack, R.
    Similowski, T.
    Cleland, J.
    Whitehead, A.
    Wise, R.
    McGarvey, L.
    John, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) : 775 - 789
  • [9] COPD exacerbations 1: Epidemiology
    Donaldson, GC
    Wedzicha, JA
    [J]. THORAX, 2006, 61 (02) : 164 - 168
  • [10] The effect of tiotropium on exacerbations and airflow in patients with COPD
    Dusser, D
    Bravo, ML
    Iacono, P
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (03) : 547 - 555